BioPharma companies that decide to expand operations into the United Kingdom face many challenges. As the UK is one of the first launch countries in Europe, gaining a price and positive recommendation for reimbursement, and setting the scene for subsequent launches is a priority.
The UK Pricing and Reimbursement system includes multiple complex processes. MAP has used experience of over 200 pricing and HTA procedures to develop this checklist, which is designed to assist you to develop a complete, validated plan to accelerate optimal patient access.
Completing this 11-point checklist will ensure that you have considered all key activities in your Market Access plan that can lead to a successful launch, allowing you to focus on the completion of each step until the product is in the market.
Copyright © 2021. MAP BioPharma Limited. All rights reserved.
MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281
VAT Group Registration Number GB 292 8576 52